Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
MK-0533
Cat. No.:
0225LY-0830
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, ORP, and LC-MS.
Size:
Add to basket
Product Overview
Description:
MK-0533 is a novel PPAR-gamma partial agonist designed to prevent vascular endothelial dysfunction (VED) and related cardiovascular diseases.
Synonym:
668455-28-5; (R)-2-(3-(3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl)phenoxy)butanoic acid; CHEMBL490029; (2R)-2-[3-[3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)indol-1-yl]phenoxy]butanoic Acid; 2-[3-[3-(4-Methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]phenoxy]-(2R)-butanoic acid
CAS No.:
668455-28-5
Compound CID:
11678534
Formula:
C28H24F3NO6
Formula Weight:
527.49
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MK-0533 can be used in pharmacological studies to explore the regulation of glucose levels through PPAR modulation.
Library Information
Target:
PPAR
Receptor:
PPARγ
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-11
Plate Location:
f9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
55 mg/mL; 104.27 mM
